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(dacarbazine and vemurafenib) in Canada from a societal perspective. Methods: 
A partitioned survival analysis model with 3 health states (pre-progression, 
post-progression, dead) estimated direct and indirect costs and quality-adjusted 
life-years (QALYs) for patients with BRAF V600+ advanced or metastatic melanoma 
receiving 1L treatment with trametinib, dacarbazine, or vemurafenib. Clinical 
inputs for trametinib and dacarbazine were from the METRIC trial (in the 1L 
chemotherapy group, 87%, 6% and 6% of patients received dacarbazine, paclitaxel, 
and no drug, respectively). Clinical inputs for vemurafenib were from an indirect 
treatment comparison of data from the METRIC and BRIM-3 studies. Resource 
utilization data were derived from physician survey results, drug costs from the 
manufacturers’ price and Quebéc medications lists, and other costs from pub-
lished sources. Consistent with a prior evaluation of vemurafenib, a 5-year time 
horizon was used. Costs and QALYs were discounted at 5% annually. Results: 
QALYs gained with trametinib were 0.4160 vs. dacarbazine and 0.1241 vs. vemu-
rafenib. Compared with dacarbazine, incremental costs for trametinib were 
$61,226, resulting in a cost of $147,177 per QALY gained. Compared to vemurafenib, 
trametinib yielded a cost savings of $26,553 and was therefore dominant (less 
costly, more effective). Probabilistic sensitivity analyses showed a 14% and 98% 
probability of trametinib being cost effective vs. dacarbazine and vemurafenib, 
respectively, based on a $100,000/QALY threshold. ConClusions: In patients with 
BRAF V600+ advanced or metastatic melanoma, 1L treatment with trametinib may 
not be cost-effective vs. dacarbazine but may be cost-effective vs. vemurafenib. 
There is uncertainty in the vemurafenib comparison given the lack of head-to-
head data.
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objeCtives: Acute promyelocytic leukemia (APL) constitutes a distinct and rare 
variant of acute myeloid leukemia and is characterized by a high early mortality 
rate. Although current treatments (all-trans retinoic acid (ATRA), anthracyclines, 
including idarubicin, IDA, and conventional chemotherapy) are associated with high 
remission rates, cytotoxic effects of chemotherapy treatment are still a concern in 
the management of newly diagnosed APL. The objective of this study was to assess, 
from a Canadian perspective, the economic impact of arsenic trioxide (ATO) +ATRA 
compared to ATRA+IDA in the treatment of newly diagnosed APL. Methods: The 
cost-effectiveness of ATO+ATRA compared to ATRA+IDA in the treatment of newly 
diagnosed APL was assessed over a lifetime horizon using a time-dependent Markov 
model. The model comprises four health states: complete remission, treatment 
failure or relapse, post-failure, and death. The length of each Markov cycle was 
one month for the first 48 months and one year thereafter. All patients started in 
the complete remission state and could move to other health states thereafter, 
according to the respective efficacy of each treatment. The model also takes into 
account the incidence of adverse events reported in a head-to-head trial. Utility or 
disutility values associated with each health state and adverse events were used 
to estimate the number of QALYs associated with each treatment. Analyses were 
conducted from both a Canadian Ministry of Health (MoH) and a societal perspec-
tive. Results: Compared with ATRA+IDA, ATRA+ATO is associated with ICERs of 
$84,092/QALY and $80,946/QALY, from a MoH and societal perspective respectively. 
Results of the probabilistic sensitivity analysis indicated that the ICER remains 
below $100,000 in 99.82% and 99.98% of the simulations from a MoH and a societal 
perspective respectively. ConClusions: This economic evaluation suggests that 
ATO+ATRA can be considered a cost-effective option for the first-line treatment of 
newly diagnosed APL patients.
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objeCtives: Partially covered self expandable metal stents (SEMS) and polyethyl-
ene stents (PES) are commonly used for distal malignant biliary obstruction. SEMS 
are more efficacious yet expensive than PES. The cost-effectiveness of both stents 
using contemporary estimates was assessed. Methods: A decision tree compar-
ing initial palliative placement of PES versus SEMS was constructed for patients 
with distal malignant biliary obstruction requiring palliation with one-year fol-
low-up. Patients underwent an endoscopic retrograde cholangiopancreatography 
(ERCP) to insert the initial stent, and were followed by a gastroenterologist every 
3 months. If the insertion failed, a percutaneous transhepatic cholangiogram was 
performed. If stent occlusion occurred, a PES was then inserted at repeat ERCP, either 
in an outpatient setting, or after admission to hospital if cholangitis was present. 
Effectiveness was expressed as the likelihood of no occlusion. Costs were measured 
in US dollars. Probabilities were issued from a recent published randomized clini-
cal trial. Results: A PES-first strategy was dominated by a SEMS-first approach. 
The average cost was $6,541 USD for initial SEMS and $19,054 USD for initial PES, 
associated with respective effectiveness probabilities of 65.6% and 13.9% (likeli-
hood of experiencing no occlusion over 12 months). Sensitivity analyses confirmed 
the robustness of these results. They are however limited by the randomized trial 
where the probabilities were derived from, with regards to sample size and gener-
alizability. ConClusions: At the time of initial endoscopic drainage for patients 
with malignant biliary obstruction undergoing palliative stenting, an initial SEMS 
approach is both more effective and less costly than a PES-first strategy, regardless 
of anticipated survival or cost setting
conducted to test the robustness of the model. Results: The base-case ACER 
was $114k/QALY for abiraterone, $85k/QALY for sipuleucel-T, and $31k/QALY for 
prednisone. The base-case ICER was $389k/QALY for abiraterone, $547k/QALY for 
sipuleucel-T. Prednisone dominates both abiraterone and sipuleucel-T in terms 
of NMB at WTP thresholds of < $400k. At WTP thresholds of < $275k, sipuleucel-
T dominates abiraterone. One-way sensitivity analyses revealed that the model 
was most sensitive to overall survival and utility inputs. Probabilistic sensitivity 
analyses showed abiraterone to be cost-effective > 50% of the time at a WTP 
of > $400k, while sipuleucel-T was cost-effective > 50% of the time at a WTP of 
> $270k. ConClusions: Neither abiraterone nor sipuleucel-T was found to be 
cost-effective compared to prednisone in the treatment of asymptomatic, pre-
docetaxel mCRPC.
PCN88
A NovEl ColorECtAl CANCEr modEl with sEssilE sErrAtEd AdENomA 
PAthwAy to EvAluAtE thE Cost-EffECtivENEss of vArious sCrEENiNg 
strAtEgiEs
Zheng P., Dinh T.
Archimedes Inc., San Francisco, CA, USA
objeCtives: Sessile serrated adenoma (SSA) was recently recognized as a sepa-
rate pathway that accounts for 10-35% of colorectal cancers (CRCs). Current CRC 
screening tests exhibit inferior performance detecting SSAs as compared to other 
lesion types. Most existing CRC models do not include the SSA pathway; thus, the 
cost effectiveness of CRC screening in the face of inferior SSA detection remains 
uncertain. We developed a novel CRC model that incorporates the SSA pathway 
to evaluate the cost-effectiveness of various screening strategies. Methods: We 
modeled CRC progression in a simulated cohort of 100,000 individuals from age 
50 to 75 that were representative of the general US population. We investigated 
several CRC screening strategies within this cohort: colonoscopy every ten years 
(Q10 COLO); fecal immunochemical testing (FIT) every one, two, or three years (Q1 
FIT, Q2 FIT or Q3 FIT); and a hybrid strategy of colonoscopy every ten years with 
FIT one, two, or three years after negative colonoscopy (COLO/FIT 1, COLO/FIT 2, 
COLO/FIT 3). The primary outcomes were cancer incidence, medical cost, quality-
adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) per QALY. 
We assumed full screening compliance. All economic outcomes were discounted 
at 3% per year. Results: All screening strategies were cost saving compared to 
no screening. The COLO/FIT 2 hybrid strategy reduced cancer incidence the most 
(59% compared to no screening) and gained the most QALYs compared to no 
screening (15,200 QALYs for every 100,000 people). Compared with the standard 
Q10 COLO strategy, COLO/FIT hybrid strategies produced ICERs of approximately 
$3,300 per QALY. ConClusions: Despite the comparatively poor performance 
of colonoscopy and FIT in detecting SSAs, our simulation results suggested that 
CRC screening would save costs and increase QALYs. Hybrid screening strate-
gies with colonoscopy and FIT were cost-effective compared to screening with 
colonoscopy alone.
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objeCtives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in 
Panamá. Methods: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed, based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime 
(35 years). The perspective was that of the National Health System of Panamá. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published stud-
ies. All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in 
United States Dollars. Costs and outcomes were discounted at 3%. One way and 
probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted in 
4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 3,557 
QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 140.768 
for BR and 125.097 for FR. ICERs were: 14.468 per QALY gained, 12.114 per LY gained 
and 10.331 per PFLY gained. In all outcomes, results were sensitive to Hazard Ratio of 
overall survival. According to the PSA, with QALYs as outcome, BR had a probability 
of 39% of being cost effective when considering the threshold of 3 times the Gross 
Domestic Product per capita (GDPPC) of Panamá (28.602). ConClusions: BR can 
be considered cost-effective compared with FR in the study population (INHL) in 
Panamá, according to the classification suggested by the World Health Organization 
[cost effective between 1 and 3 GDPPC (9534-28602)].
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objeCtives: The METRIC trial demonstrated clinical benefits of trametinib vs. 
chemotherapy (dacarbazine or paclitaxel) in patients with BRAF V600+ advanced or 
metastatic melanoma overall, and in a subgroup receiving 1L treatment. We evalu-
ated the cost-effectiveness of trametinib as a 1L treatment vs. approved treatments 
